Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation combo for nasal cancer: proton vs. photon in major trial

NCT ID NCT06846450

Disease control Sponsor: Lin Kong, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial is testing whether proton radiation therapy plus carbon ion therapy works as well as standard photon radiation plus carbon ion for newly diagnosed nasopharyngeal carcinoma. About 470 participants will be randomly assigned to one of the two radiation types. The study aims to see if the newer proton approach can match the standard in controlling cancer while possibly causing fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (proton or photon) plus carbon ion radiation therapy
What this could lead to
If successful, this could show that proton radiation plus carbon ion therapy is as effective as standard photon therapy but with fewer side effects for people with nasopharyngeal cancer.
What could go wrong
This is a non-inferiority trial, so it may only confirm that proton therapy is not worse than photon therapy, not necessarily better. Side effects from radiation, including carbon ion therapy, can still be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 470 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Willingness to sign the written informed consent. * Pathologically confirmed Nasopharyngeal carcinoma. * Patients with any stage of disease except distant metastasis. * Age: ≥ 18 and ≤ 70 years old. * Eastern Cooperative Oncology Group score: 0-1. * Adequate laboratory test results. * Willingness to accept adequate contraception. Exclusion criteria: * Presence of distant metastasis. * Previous radiotherapy to head and neck region. * Previous surgery (except for biopsy) for the primary lesion or cervical lymph nodes. * History of malignant tumor within the past 5 years. * Presence of multiple primary tumors. * Presence of diseases that may interfere with the evaluation of study endpoints. * Presence of severe major organ dysfunction. * Mental illness that may affect the understanding of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal cancinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal cancinoma (NPC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Proton and Heavy Ion Center

    RECRUITING

    Shanghai, Shanghai Municipality, 201321, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.